Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.80 |
| ▸ | HTR2C | P28335 | 10/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573192 | 0.89 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3142926 | 0.89 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3136020 | 0.86 | HTR2A (1.00) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3144147 | 0.84 | HTR2A (0.77) | HTR2AHTR2CKCNH2HSD17B10 | |
| SCHEMBL29572905 | 0.84 | HTR2A (0.77) | HTR2AHTR2CKCNH2HSD17B10 | |
| SCHEMBL29572880 | 0.83 | HTR2A (0.78) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3144161 | 0.83 | HTR2A (0.78) | HTR2AHTR2CKCNH2 | |
| SCHEMBL3142912 | 0.79 | HTR2A (0.83) | HTR2AHTR2CKCNH2HSD17B10 | |
| SCHEMBL3143488 | 0.78 | HTR2A (0.76) | HTR2AHTR2CKCNH2HSD17B10 | |
| SCHEMBL29573378 | 0.77 | HTR2A (0.78) | HTR2AHTR2CKCNH2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190160043-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF REM SLEEP BEHAVIOR DISORDER | AXOVANT SCIENCES LTD. (BM) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160043-A1 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF REM SLEEP BEHAVIOR DISORDER | HTR2A, HTR2C, HTR2B | HTR2A 1/4885HTR2C 2/4885KCNH2 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.